On May 5, 2022, the Board of Directors of China Pharmaceutical Innovation and Research Development Association (“PhIRDA”) voted to approve ZSHK's application for membership of PhIRDA. Upon the approval, ZSHK officially became a member of the PhIRDA family.
   
  Founded in 1988, China Pharmaceutical Innovation and Research Development Association (“PhIRDA”), formerly named China Pharmaceutical Industry Research and Development Association, is registered as a non-profit 4A social organization by the Ministry of Civil Affairs of China at national level. PhIRDA has been exerting great effort on “academia-industry-investment collaboration”, which centers on the principle of “innovation, industrialization, internationalization”, and persists in innovation to achieve unmet clinical requirements. As a platform facilitating the industrialization of pharmaceutical innovation, PhIRDA currently has 171 members mainly consists of pharmaceutical R&D enterprises, research institutions, clinical institutions, R&D Services companies and investment institutions focusing on pharmaceutical innovation. Moreover, PhIRDA has established the following Specialty Committees: Drug R&D, Clinical Trial Research, Medicinal Policy, Pharmaceutical Innovation Investment and Innovation R&D Services, Clinical Research on Cardiovascular Drugs, International Regulatory Science, Clinical Research on Oncology Drugs, Clinical Research on Cranial Nerve Drugs, Ethics and Business Compliance, Clinical Research on Diabetes and Metabolic Diseases, forming a fully functional organization structure focusing on innovation, aiming to promote the development of innovation, covering the whole industrial chain, including drug R&D, manufacturing, using, investment and capital market. PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.
  ZSHK Laboratories Limited (“ZSHK”) is a biopharmaceutical pre-clinical research and development service company. Its main business is pre-clinical research and evaluation services for drugs and medical devices. A one-stop R&D service platform, it renders research services in pharmacology and pharmacodynamics, pharmacokinetics, safety evaluation and other services for pharmaceutical companies and R&D organizations worldwide. ZSHK has independent laboratories in Hong Kong Science and Technology Park, Pingshan District of Shenzhen, Guangdong Province, and Suzhou Industrial Park of Jiangsu Province. Actively deploying R&D supply chain construction, ZSHK has established breeding and scientific research bases in Hunan for experimental dogs and Guangxi for non-human primates.
 
Source link: https://mp.weixin.qq.com/s/5tu8t8AA09v-AvphZuy-AQ